|
|
Publicaciones I (Período 2003 -2008) Servicio de Oncología Médica Hospital Universitario de Salamanca |
| Publicaciones relacionadas directamente con ensayos clínicos | ||
|
1 |
Biweekly
Docetaxel and Vinorelbine in Anthracycline-Resistant metastatic breast
cancer. A multicenter phase II study. A. Gómez-Bernal, J.J. Cruz, A.García-Palomo, A. Arizcun, E. Pujol, P. Diez, G. Martín, E. Fonseca, P. Sánchez, C. A. Rodríguez, E.del Barco, Y.López. American Journal of Clinical Oncology 2003; 127: 121-128. Índice de impacto 1.224 |
|
| 2 | A
multicenter phase II study of Irinotecan in Patients with advanced
colorectal cancer previously treated with 5-Fluorouracil. Miguel Méndez, Antonieta Salut, Carlos García-Girón, Marta Navalón, Pilar Diz, Mª José García López, Pilar España, Ascensión de la Torre, Purificación Martínez del Prado, Isabel Duarte, Eduardo Pujol, Alberto Arizcum, Juan Jesús Cruz. Clinical Colorectal Cancer, Vol. 3, No. 3, 174-179, 2003. |
|
| 3 | Her-2/
neu Gene Amplification in Familial vs Sporadic Breast Cancer. Impact on
the Behavior of the Disease. Ana B. Espinosa, PhB, María D. Tabernero, MD, Maria C. García Macías, Daniel Primo, PhD,Amalia Gómez Bernal, MD, Juan J. Cruz, MD,PhD, Manuel Ramos, MD, Jaime Font de Mora, PhD, Alberto Gómez Alonso, MD, PhD, and Alberto Orfao, MD, PhD. Clin Pathol 2003; 120: 917-927. Índice de impacto 5.917. |
|
| 4 |
Phase
II study of carboplatin and 1-h intravenous etoposide and paclitaxel in
a novel sequence as first-line treatment of patients with |
|
| 5 | Combination
of low-dose cisplatin and gemcitabine for treatment of elderly patients
with advanced non-samll-cell luna cancer. Feliú J, Martín G, Madroñal C, Rodríguez- Jaraiz A, Castro J, Rodríguez A, Checa T, Bolaño M, Casado E, González Barón M Cancer Chemother Pharmacol 2003; 52: 247-252. |
|
| 6 |
Experiencia
del hospital universitario de Salamanca en el tratamiento sistémico
adyuvante del cáncer de mama locorregional. |
|
| 7 | Biweekly
Docetaxel and Vinorelbine with granulocite
colony-stimulating factor support for patients
with anthra cycline- resistant metastatic breast cancer. Gómez Bernal A., Cruz JJ., Olaverri A., Arizcun A., Martín T., Rodríguez CA., Martín G., Fonseca E., Sánchez P. Anticancer Drugs. 2005 Jan; 16 (1): 77-82. Índice de impacto 2.245 |
|
| 8 |
Weekly
irinotecan plus UFT and leucovorin as first-time chemotherapu of
patients with advanced
colorectal cancer. |
|
| 9 |
Induction
chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluoracil
for locally advanced squamous cell carcinoma
of |
|
| 10 |
Randomized,
Double-Blind, Active-Controlled Trial of Every-3-Week Darbepoetin Alfa
for the Treatment of Chemotherapy- |
|
| 11 |
Docetaxel
and mitomycin as second-line treatment in advanced non-small cell lung
cancer. |
|
| 12 |
Gemcitabine
plus vinorelbine versus vinorelbine monotherapy
in patients with metastatic breast cancer
previously treated with anthracyclines and taxanes: final results of the phase III spanish breast cancer research group (Geicam) trial. Martín M, Ruiz A, Muñoz M, Balil A, García-Mata J, Calvo L, Carrasco E, Casado A, García-Saenz J.A., Escudero MJ, Guillem V, Jara C, Ribelles N, Salas F, Soto C, Morales-Vasquez F, Rodríguez C. A., Adrover E, Mel JR. Lancet Oncology 2007; 8:219-225 |
|
| 13 |
Advanced breast cancer: phase III trials that
change a standard. |
|
| 14 |
The
Use of taxanes in the neoadjuvant treatment of breast cancer; a review
of randomized phase II and phase III trials. |
|
| 15 |
Advanced
breast cancer: chemotherapy phase III trials that change a standard. |
|
____________________________________________________________
Servicio
de Oncología Médica del Hospital Clínico Universitario de Salamanca 2008 # #
webmaster